To evaluate the efficacy and safety of intravenous micafungin for the treatment of patients with proven or probable fungal infections caused by Candida sp. (Fungemia, respiratory mycosis, gastrointestinal mycosis) in adult patients in China.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
59
Intravenous (IV)
Unnamed facility
Beijing, China
Unnamed facility
Changsha, China
Unnamed facility
Chengdu, China
Unnamed facility
Fuzhou, China
Overall success rate
success rate is calculated as (number of success patients/number of patients for efficacy evaluation × 100% at end of treatment)
Time frame: up to 8 weeks
Safety assessed by the incidence of adverse events
Time frame: up to 10 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Guangzhou, China
Unnamed facility
Harbin, China
Unnamed facility
Hengyang, China
Unnamed facility
Jinan, China
Unnamed facility
Nanjing, China
Unnamed facility
Shanghai, China
...and 5 more locations